The biotech is entering a new era.

President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma support a broader effort ...

Moderna built an artificial intelligence that reads a patient’s tumor and decides what that patient’s medicine should be.

Moderna just surged 8% on a morning when its closest cancer-vaccine peer barely budged and its own pipeline partner slipped ...

Moderna (MRNA) closed at $146.69 in the latest trading session, marking a +1.89% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.48%. At the same time, ...

Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized ...

Florida pharmacies and clinics are now offering updated flu and COVID vaccines for the 2026-27 respiratory illness season, ...

Moderna and Merck's Phase 3 melanoma vaccine trial showed positive results, but full data and FDA approval are still pending ...

A year to the day after the Trump administration slashed $500 million in funding from mRNA-based programs, the FDA approved ...

Dow Jones futures: Despite Friday's bounce, the stock market had a tough week amid $100 oil prices and surging Treasury ...

A cancer vaccine breakthrough sent Moderna's stock up more than 176% before a sharp pullback — a reminder of the risks ...

Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a ...